Showing results (1-10 of 329) with videos related to
Sort By:
Pageof 33
Breast Cancer (Tokyo, Japan)|February 17, 2018
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)Shinzaburo Noguchi, Matthew J Ellis, John F R Robertson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON TrialJohn F R Robertson, Zhimin Shao, Shinzaburo Noguchi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST studyJohn F R Robertson, Antonio Llombart-Cussac, Janusz Rolski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST StudyMatthew J Ellis, Antonio Llombart-Cussac, David Feltl, et al.The Oncologist|August 4, 2007
Fulvestrant (Faslodex) -- how to make a good drug betterJohn F R RobertsonEuropean Journal of Cancer (Oxford, England : 1990)|March 26, 2018
Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancerJohn F R Robertson, Kwok-Leung Cheung, Shinzaburo Noguchi, et al.Cancer Treatment Reviews|November 16, 2004
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspectiveJohn F R RobertsonBreast Cancer Research and Treatment|October 16, 2012
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' studyJohn F R Robertson, Justin P O Lindemann, Antonio Llombart-Cussac, et al.Breast (Edinburgh, Scotland)|July 4, 2017
Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancerMatthew J EllisAnnals of Surgical Oncology|March 16, 2004
Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapyMatthew J EllisPageof 33